YuanDong Bio Stock Surges Over 11% as Phase 1 Anti-Tumor Drug Trial Begins

YuanDong Bio's stock price surged by more than 11% on Friday following the company's announcement that its Phase I clinical trial for a new anti-tumor drug, YLSH003, has officially commenced. The market's positive reaction highlights investor optimism surrounding the new drug's potential.